KRSA (33) OMER (46) DMRA (47) ANAB (61) ⌘ Pro Terminal →

Ascentage Pharma Group International American Depository Shares (AAPG) — RQD Stock Rating Cockpit

$14.88 -0.70% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $14.83

Ascentage Pharma Group International American Depository Shares (AAPG) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $1.39B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AAPG Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AAPG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-01, Ascentage Pharma Group International American Depository Shares (NASDAQ: AAPG) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $14.88 (-0.70% 1D, market cap $1.39B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, AAPG ranks #252 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AAPG compare to KRSA and OMER in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AAPG carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, KRSA (Korsana Biosciences Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -5.7%, cap $1.38B) and OMER (Omeros Corporation) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $1.37B). Among the 5-stock peer group, AAPG leads on earnings multiple (N/A) while ANAB leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AAPG?

▼

For Ascentage Pharma Group International American Depository Shares (AAPG), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #252 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $14.83 (-0.32%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY • 52.2% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE-0.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AAPG)Realized 20D OHLCV Swing Band: ±6.8%

Deterministic 5-Pillar Attribution (57/100 Composite)

🔍 WHY AAPG SCORES 57/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (26% of score)

FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 42.1 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$14.75+4.2% Next Q

Q2 (-2Q)

Grade C-$15.37+0.5% Next Q

Q3 (-1Q)

Grade C-$15.44-3.6% Next Q

Current

Grade D+$14.88-0.2% Hist 90D α

Trajectory: D (49) → D+ (57)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the AAPG Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 57/100 (D+) score, AAPG faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($15.87) or 200D SMA ($20.15) invalidates the momentum regime and cuts Target Base ($14.81) toward Bear Floor ($11.55).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AAPG• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “AAPG Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 57%NO 43%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

42.130 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE4% OF RANGE

L: $14$14.88H: $35

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 17 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B-RQD 28 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on AAPG

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (53)

17/40 institutional & smart-money positioning score with 15/20 macro alignment.

Bull Case: Why Buyers Like AAPG

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AAPG)

✓Walkthrough of AAPG's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AAPG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -34.97%▼ DESCENDING CHANNEL

2026-10-30O $14.45H $14.88L $13.99C $14.88VOL 15.9K

RES: $16.17SUP: $13.27SMA50: $15.87SMA200: $20.15

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AAPG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AAPG Butterfly Map → + Track AAPG →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AAPG today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AAPG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AAPG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AAPG)

Health Care Rank #252 of 1016 ⚔️ KRSA vs AAPG Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AAPG vs. KRSA, OMER, DMRA, ANAB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Ascentage Pharma Group International American Depository Shares (AAPG) ranks #252 by composite RQD confidence (57/100, grade D+) and #312 by equity capitalization ($1.39B). Within this direct 5-issuer industry benchmark cohort, AAPG leads on earnings valuation at N/A trailing P/E, while ANAB leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. ANAB currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with AAPG at 57/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AAPG ACTIVE Ascentage Pharma Group International American Depository Shares	D+	57/100	—	—	—	-0.70%	$1.39B	Benchmark Subject
KRSA Korsana Biosciences Inc.	E	33/100	—	—	-5.7%	+0.37%	$1.38B	/krsa-vs-aapg →
OMER Omeros Corporation	D	46/100	—	—	-35.0%	+5.98%	$1.37B	/omer-vs-aapg →
DMRA Damora Therapeutics Inc.	D	47/100	—	—	-35.0%	+1.85%	$1.36B	/dmra-vs-aapg →
ANAB AnaptysBio Inc.	C-	61/100	—	—	85.0%	-3.68%	$1.44B	/anab-vs-aapg →

2. AAPG Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Ascentage Pharma Group International American Depository Shares (AAPG) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $1.39B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. AAPG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AAPG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does AAPG compare to KRSA and OMER in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for AAPG?

Where is AAPG trading relative to its 50-day, 200-day, and 52-week technical levels?

AAPG last traded at $14.88 (-0.70% on volume of 11,298 shares), positioning the stock -6.24% below its 50-day simple moving average ($15.87) and -26.15% below its 200-day simple moving average ($20.15). Across its 52-week range of $13.99 to $34.50, AAPG sits at the 4.3% percentile with a 14-day RSI of 42.1 (NEUTRAL RANGE) and an implied next-earnings move of ±6.8% ($13.87 to $15.89).

AAPG Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell AAPG stock right now?

Ascentage Pharma Group International American Depository Shares (AAPG) currently earns a Roarable Rating of D+ (Sell — SELL) with 57/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is AAPG's 12-month price target and RQD AI Jury consensus?

AAPG's 12-month base price target is $14.81 (range $11.55 to $36.23), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: AAPG RQD Cockpit AAPG 12M Forecast AAPG Earnings & Move AAPG Dividends & DRIP AAPG Insiders & 13F AAPG Whale Options AAPG Profit Sankey AAPG News & Why